Search for a clinical trial
Other search option(s)
18 Result(s)
Recruiting trial
= 
; Ongoing trial
= 
; Funded by an IRDiRC member = 
; Member of a ERN = 
National clinical trial(s)
BELGIUM
VLAAMS BRABANT
LEUVEN
PEDFIC 1: A Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study to Demonstrate Efficacy and Safety of A4250 in Children with Progressive Familial Intrahepatic Cholestasis Types 1 and 2 - BE
UZ Leuven - Campus Gasthuisberg
Dienst Kindergeneeskunde/Department of Pediatrics
GERMANY
Nordrhein-Westfalen
ESSEN
PEDFIC 1: A Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study to Demonstrate Efficacy and Safety of A4250 in Children with Progressive Familial Intrahepatic Cholestasis Types 1 and 2 -DE-
Universitätsklinikum Essen
EZSE - Essener Zentrum für Seltene Erkrankungen
SPAIN
Cataluña
BARCELONA
PEDFIC 2: An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of A4250 in Children with Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (Phase III) - ES
Hospital Universitari Vall d'Hebron
SPAIN
Madrid
MADRID
PEDFIC 2: An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of A4250 in Children with Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (Phase III) - ES
Hospital Universitario La Paz
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
MARCH-PFIC: Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Subjects With Progressive Familial Intrahepatic Cholestasis - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
MRX-503: An Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of Maralixibat in the Treatment of Subjects with Progressive Familial Intrahepatic Cholestasis (PFIC) - AT
Institution: Information not provided - AT
BELGIUM
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
MERGE - MRX-800: A Long-Term Safety Study of Maralixibat, an Apical Sodium Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study - BE
Institution: Information not provided - BE
BELGIUM
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
MRX-503: An Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of Maralixibat in the Treatment of Subjects with Progressive Familial Intrahepatic Cholestasis (PFIC) - BE
Cliniques universitaires Saint-Luc - UCLouvain
Service d'hépato-gastro-entérologie
BELGIUM
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
MRX-502/MARCH-PFIC: Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Subjects With Progressive Familial Intrahepatic Cholestasis - BE
Cliniques universitaires Saint-Luc - UCLouvain
Service d'hépato-gastro-entérologie
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
MRX-503: An Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of Maralixibat in the Treatment of Subjects with Progressive Familial Intrahepatic Cholestasis (PFIC) - FR
Institution: Information not provided - FR
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
MERGE - MRX-800: A Long-Term Safety Study of Maralixibat, an Apical Sodium Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study - FR
Institution: Information not provided - FR
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
MRX-503: An Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of Maralixibat in the Treatment of Subjects with Progressive Familial Intrahepatic Cholestasis (PFIC) - DE
Institution: Information not provided - DE
ITALY
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
MRX-503: An Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of Maralixibat in the Treatment of Subjects with Progressive Familial Intrahepatic Cholestasis (PFIC) - IT
Institution: Information not provided - IT
SPAIN
Madrid
MADRID
MRX-800: A Long-Term Safety Study of Maralixibat, an Apical Sodium Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study (Phase II) - ES
Hospital Universitario La Paz
UNITED KINGDOM
West Midlands
BIRMINGHAM
INDIGO STUDY - An open label study of the efficacy and long term safety of lum001, an apical sodium-dependent bile acid transporter inhibitor (asbti), in the treatment of cholestatic liver disease in pediatric patients with progressive familial intrahepatic cholestasis
Birmingham Children's Hospital NHS Foundation Trust
Birmingham Children's Hospital
Multinational clinical trial(s)
SWEDEN
Region Stockholm
ADDRESS: NOT PROVIDED - SE
PEDFIC 1: A Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study to Demonstrate Efficacy and Safety of A4250 in Children with Progressive Familial Intrahepatic Cholestasis Types 1 and 2
Institution: Information not provided - SE
UNITED STATES
California
FOSTER CITY
MRX-503: An Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of Maralixibat in the Treatment of Subjects with Progressive Familial Intrahepatic Cholestasis (PFIC)
Mirum Pharmaceuticals, Inc.
UNITED STATES
California
FOSTER CITY